Texas
LATEST FROM BIOSPACE
Nuravax is developing an Alzheimer’s vaccine to induce therapeutically potent concentrations of antibodies against pathological proteins. Know more here.
ReCode is aiming to advance its lead candidates for cystic fibrosis and primary ciliary dyskinesia (PCD).
More than $170 million was paid out for drugs that manufacturers voluntarily withdrew from the market after subsequent trials showed no benefit in overall survival.
Broad announced that it is bringing René Salazar on board as its first chief equity officer.
It’s only the second week of October, and the biopharma IPO scene has already been buzzing this month.
The idea is not just a flight of fancy by a brilliant mind with big dreams. It is part of a larger de-extinction strategy aimed at solving climate change.
Here’s a look at a few of the industry expansions that have been announced so far this month.
Cassava Sciences announced top-line results Wednesday from a 12-month interim analysis of its Alzheimer’s drug candidate simufilam.
Triumvira’s inaugural program is directed against HER2, a well-known tumor-associated antigen that is expressed in multiple tumors.
During the past two years, fundraising and investment in biotechnology have reached record levels.
PRESS RELEASES